Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data
| Filename | 298. Staubach et al., X-ACT Oma rapidly improves AE, Allergy 2018.pdf |
| Filesize | 500.27 KB |
| Version | o.298 |
| Date added | July 28, 2020 |
| Downloaded | 2 times |
| Category | Original Work |
| Tags | angioedema, chronic spontaneous urticaria, H1-antihistamine-refractory, omalizumab, Quality of life |
| Authors | Staubach, P., Metz, M., Chapman-Rothe, N., Sieder, C., Bräutigam, M., Maurer, M. and Weller, K. |
| Citation | Staubach, P., Metz, M., Chapman-Rothe, N., Sieder, C., Bräutigam, M., Maurer, M. and Weller, K.: Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy 2018: 73; 576-584. |
| Corresponding authors | Weller, K |
| DocNum | O.298 |
| DocType | |
| Edition; Page | 73; 576-584 |
| IF | 6.77 |
| Publisher | Allergy |
| ReleaseDate | 2018 |
Background:The X-ACT study aimed to examine the effect of omalizumab treat-ment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients withangioedema refractory to high doses of H1-antihistamines.
Methods:In X-ACT, a phase III, double-blind, placebo-controlled study, CSUpatients (18-75 years) with≥4 angioedema episodes during the 6 months beforeinclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every4 weeks for 28 weeks. Angioedema-related QoL, skin-related QoL impairment, andpsychological well-being were assessed.
Results:Ninety-one patients were randomized and 68 (omalizumab, n=35; placebo,n=33) completed the 28-week treatment period. At baseline, the mean (SD) totalAngioedema QoL (AE-QoL; 56.2 [18.7] and 59.9 [19.2]) and Dermatology Life QualityIndex (DLQI; 14.6 [5.7] and 16.6 [7.3]) score were high in the omalizumab and placebogroup, respectively. At Week 4 (after the first treatment), the least squares mean dif-ference in the AE-QoL and DLQI score between groups was17.6 (P<.001) and7.2 (P<.001), respectively. Significant QoL improvements in the omalizumab vs pla-cebo groups continued until Week 28, but returned to placebo levels at the follow-upvisit. The mean (SD) baseline 5-item World Health Organization Well-being Index was10.0 (5.5, omalizumab) and 7.7 (5.3, placebo), which increased above the depressionthreshold (<13) from Week 4 and throughout with omalizumab but not placebo treat-ment. Compared to placebo, omalizumab was also associated with decreased fear ofsuffocation due to angioedema.
Conclusions:Our findings support omalizumab treatment in patients with severeH1-antihistamine-refractory CSU with angioedema.
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.